In the developed world, conditions such as advanced Retinitis Pigmentosa (RP), age-related macular degeneration (AMD), and diabetic retinopathy – all characterized by photoreceptor loss – are the main causes of registered blindness.
In this regard, there are no currently effective treatments for patients suffering from Geographic Atrophy (GA) as a consequence of dry age-related macular degeneration (dry-AMD) and RP, leaving approximately 2.6 million people across Europe and over 5 million worldwide with the risk of developing severe visual impairments. Standard techniques to treat GA and DR, including Intravitreal Injections (IVTs) and subretinal transplantation present major problems associated with them.
Everads developed a treatment for macular and retinal degeneration, utilizing the innovative Everads Injection System (EIS), a minimally-invasive platform for optimal injection of Adult Bone Marrow Mesenchymal Stromal Cells (hBM-MSCs). unique treatment approach allows simple, office-based safe transplantation of hBM-MSCs in the matrix between the choroidal blood vessels, providing excellent distribution very close to the target organ (retina) and long-term therapeutic effects, targeting multi-billion market opportunities.
The Everads treatment is safe, minimally-invasive, can be performed in an office setting and ensures 80% drug distribution in the retinal area, aiming for longer lasting effect of drug. It also reduces the risk of side-effects like increased Intra Ocular Pressure (IOP), glaucoma, cataract typical of IVT injections.